AXSM - Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.30 revenue of $46.01M beats by $5.06M
2023-08-07 07:01:35 ET
- Axsome Therapeutics press release ( NASDAQ: AXSM ): Q2 GAAP EPS of -$1.54 misses by $0.30 .
- The net loss in the second quarter of 2023 reflects $23.6 million in non-cash charges, comprised of $15.9 million of non-cash stock-based compensation expense, $6.1 million of non-cash loss in fair value of contingent consideration, and $1.6 million of non-cash intangible asset amortization.
- Revenue of $46.01M (+421.7% Y/Y) beats by $5.06M .
- Total product revenue for the second quarter of 2023 was $46.7 million, consisting of net product sales of $46.0 million and royalty revenue of $0.7 million. Total product revenue for the comparable period in 2022 was $8.8 million.
For further details see:
Axsome Therapeutics GAAP EPS of -$1.54 misses by $0.30, revenue of $46.01M beats by $5.06M